SEARCH

SEARCH BY CITATION

References

  • 1
    Brenner DE. New paradigms in oncological therapeutics: redefining combination chemotherapy. Ann Oncol 2002; 13: 16978.
  • 2
    Leamon CP,Low PS. Delivery of macromolecules into living cells: a method that exploits folate receptor endocytosis. Proc Natl Acad Sci USA 1991; 88: 55726.
  • 3
    Kamen BA,Capdevila A. Receptor-mediated folate accumulation is regulated by the cellular folate content. Proc Natl Acad Sci USA 1986; 83: 59837.
  • 4
    Boerman OC,van Niekerk CC,Makkink K,Hanselaar TG,Kenemans P,Poels LG. Comparative immunohistochemical study of four monoclonal antibodies directed against ovarian carcinoma-associated antigens. Int J Gynecol Pathol 1991; 10: 1525.
  • 5
    Garin-Chesa P,Campbell I,Saigo PE,Lewis JL,Old LJ,Rettig WJ. Trophoblast and ovarian cancer antigen LK26. Am J Pathol 1993; 142: 55767.
  • 6
    Weitman SD,Lark RH,Coney LR,Fort DW,Frasca V,Zurawski VR,Kamen BA. Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues. Cancer Res 1992; 52: 3396401.
  • 7
    Mattes MJ,Major PP,Goldenberg DM,Dion AS,Hutter RVP,Klein KM. Patterns of antigen distribution in human carcinomas. Cancer Res Suppl 1990; 50: 880S.
  • 8
    Coney LR,Tomassetti A,Carayannopoulos L,Frasca V,Kamen BA,Colnaghi MI,Zurawski VRJ. Cloning of a tumor-associated antigen: MOv18 and MOv19 antibodies recognize a folate-binding protein. Cancer Res 1991; 51: 612532.
  • 9
    Weitman SD,Frazier KM,Kamen BA. The folate receptor in central nervous system malignancies of childhood. J Neurol Oncol 1994; 21: 107.
  • 10
    Toffoli G,Cernigoi C,Russo A,Gallo A,Bagnoli M,Boiocchi M. Overexpression of folate binding protein in ovarian cancers. Int J Cancer 1997; 74: 1938.
  • 11
    Holm J,Hansen SI,Hoier-Madsen M,Bostad L. High-affinity folate binding in human choroid plexus. Characterization of radioligand binding, immunoreactivity, molecular heterogeneity and hydrophobic domain of the binding protein. Biochem J 1991; 280 (Part 1): 26771.
  • 12
    Parker N,Turk MJ,Westrick E,Lewis JD,Low PS,Leamon CP. Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. Anal Biochem 2005; 338: 28493.
  • 13
    Patrick TA,Kranz DM,van Dyke TA,Roy EJ. Folate receptors as potential therapeutic targets in choroid plexus tumors of SV40 transgenic mice. J Neurooncol 1997; 32: 11123.
  • 14
    Leamon CP,Reddy JA,Vlahov IR,Kleindl PJ,Vetzel M,Westrick E. Synthesis and biological evaluation of EC140: a novel folate-targeted vinca alkaloid conjugate. Bioconjug Chem 2006; 17: 122632.
  • 15
    Leamon CP,Reddy JA,Vlahov IR,Vetzel M,Parker N,Nicoson JS,Xu LC,Westrick E. Synthesis and biological evaluation of EC72: a new folate-targeted chemotherapeutic. Bioconjug Chem 2005; 16: 80311.
  • 16
    Ross JF,Chaudhuri PK,Ratnam M. Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Physiologic and clinical implications. Cancer 1994; 73: 243243.
  • 17
    Reddy JA,Westrick E,Vlahov I,Howard SJ,Santhapuram HK,Leamon CP. Folate receptor specific anti-tumor activity of folate-mitomycin conjugates. Cancer Chemother Pharmacol 2006; 58: 22936.
  • 18
    Low PS,Antony AC. Folate receptor-targeted drugs for cancer and inflammatory diseases. Adv Drug Deliv Rev 2004; 56: 1055238.
  • 19
    Leamon CP,Reddy JA. Folate-targeted chemotherapy. Adv Drug Deliv Rev 2004; 56: 112741.
  • 20
    Xu L,Vlahov IR,Leamon CP,Santhapuram HKR,Li CH. Synthesis, purification, and uses of pteroic acid and derivatives and conjugates thereof. Patent application number PCT/US2006/009153 2005, March 14, 2006.
  • 21
    Vlahov IR,Santhapuram HK,Kleindl PJ,Howard SJ,Stanford KM,Leamon CP. Design and regioselective synthesis of a new generation of targeted chemotherapeutics. Part 1, EC145, a folic acid conjugate of desacetylvinblastine monohydrazide. Bioorg Med Chem Lett 2006; 16: 50936.
  • 22
    Westerhof GR,Schornagel JH,Kathmann I,Jackman AL,Rosowsky A,Forsch RA,Hynes JB,Boyle FT,Peters GJ,Pinedo HM,Jansen G. Carrier- and receptor-mediated transport of folate antagonists targeting folate-dependent enzymes: correlates of molecular structure and biological activity. Mol Pharm 1995; 48: 45971.
  • 23
    Mathias CJ,Wang S,Lee RJ,Waters DJ,Low PS,Green MA. Tumor-selective radiopharmaceutical targeting via receptor-mediated endocytosis of Gallium-67-deferoxamine-folate. J Nucl Med 1996; 37: 10038.
  • 24
    Lee FY,Borzilleri R,Fairchild CR,Kim SH,Long BH,Reventos-Suarez C,Vite GD,Rose WC,Kramer RA. BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin Cancer Res 2001; 7: 142937.
  • 25
    Rose WC. Taxol-based combination chemotherapy and other in vivo preclinical antitumor studies. J Natl Cancer Inst Monogr 1993: 4753.
  • 26
    Bae Y,Nishiyama N,Fukushima S,Koyama H,Yasuhiro M,Kataoka K. Preparation and biological characterization of polymeric micelle drug carriers with intracellular pH-triggered drug release property: tumor permeability, controlled subcellular drug distribution, and enhanced in vivo antitumor efficacy. Bioconjug Chem 2005; 16: 12230.
  • 27
    Yang J,Chen H,Vlahov IR,Cheng JX,Low PS. Evaluation of disulfide reduction during receptor-mediated endocytosis using fluorescence resonance energy transfer imaging. Proc Natl Acad Sci USA 2006; 103: 138727.
  • 28
    Laguzza BC,Nichols CL,Briggs SL,Cullinan GJ,Johnson DA,Starling JJ,Baker AL,Bumol TF,Corvalan JR. New antitumor monoclonal antibody-vinca conjugates LY203725 and related compounds: design, preparation, and representative in vivo activity. J Med Chem 1989; 32: 54855.
  • 29
    Boyd MR. The NCI in vitro anticancer drug discovery screen. In: TeicherB, ed. Anticancer drug development guide: preclinical screening, clinical trials, and approvaled. Totowa: Humana Press, 1997. 2342.
  • 30
    Leamon CP,Parker MA,Vlahov IR,Xu LC,Reddy JA,Vetzel M,Douglas N. Synthesis and biological evaluation of EC20: a new folate-derived 99mTc-based radiopharmaceutical. Bioconjug Chem 2002; 13: 120010.
  • 31
    Goren D,Horowitz AT,Tzemach D,Tarshish M,Zalipsky S,Gabizon A. Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump. Clin Cancer Res 2000; 6: 194957.
  • 32
    Klykken PC,Loveless SE,Morahan PS,Munson AE. Responsiveness of the madison 109 lung carcinoma to maleic vinyl ether copolymer. J Immunopharmacol 1983; 5: 3147.
  • 33
    Paulos CM,Reddy JA,Leamon CP,Turk MJ,Low PS. Ligand binding and kinetics of folate receptor recycling in vivo: impact on receptor-mediated drug delivery. Mol Pharmacol 2004; 66: 140614.
  • 34
    Birn H,Selhub J,Christensen EI. Internalization and intracellular transport of folate-binding protein in rat kidney proximal tubule. Am. J Physiol C 1993; 264: C302C310.
  • 35
    Birn H,Nielsen S,Christensen EI. Internalization and apical-to-basolateral transport of folate in rat kidney proximal tubule. Am J Physiol 1997; 272: F70F78.